Cabernet Pharmaceuticals, One Science Drive, Box 90344, Durham NC 27708, USA.
Curr Pharm Des. 2009;15(32):3754-63. doi: 10.2174/138161209789649538.
There has been a decline in the number of new drugs registered over the past decade and regulatory concerns for safety as well as payer concerns for efficacy have focused attention on stratified medicine. Integration of pharmacogenetics into the drug development pipeline will contribute to the development of new stratified drugs. We describe here the concept of pipeline pharmacogenetics and its application throughout the phases of drug discovery. Pipeline pharmacogenetics enables the evaluation of the genetic contribution to safety potentially lowering barriers to registration as well as providing rationale for efficacy and enabling co-development of genetic in vitro diagnostics.
在过去的十年中,新注册药物的数量有所下降,监管部门对安全性的关注以及支付方对疗效的关注,都使得分层医学成为关注焦点。将药物遗传学纳入药物开发管道将有助于开发新的分层药物。在这里,我们描述了管道药物遗传学的概念及其在药物发现各个阶段的应用。管道药物遗传学能够评估安全性方面的遗传贡献,从而降低注册障碍,并为疗效提供依据,同时还能促进遗传体外诊断的共同开发。